From the analyst’s couch: The dyslipidemia market on Nature Reviews Drug Discovery.
By Victoria Hudson, Senior Analyst
27 October 2014
I am the senior analyst for Datamonitor Healthcare’s cardiovascular and metabolic team, and cover everything from acut...
Read full bio
Datamonitor Healthcare analyst, Victoria Hudson, has written an article for Nature Reviews Drug Discovery discussing the dyslipidaemia market. The article is currently live on their website here and will be published in the November issue.
It is estimated that the annual global number of deaths that are attributable to cardiovascular diseases (CVDs) will rise to 23.3 million by 2030. Dyslipidaemia which refers to any deviations in lipid levels from defined normal parameters, is a major modifiable risk factor for CVDs. The most common deviations include elevated low-density lipoprotein (LDL) cholesterol (LDL‑C; also known as ‘bad’ cholesterol), elevated triglycerides, and reduced high-density lipoprotein (HDL) cholesterol (HDL‑; also known as ‘good’ cholesterol). Excessively elevated LDL‑ levels can lead to atherosclerosis when cholesterol is deposited in plaques in arterial walls. These plaques can rupture, leading to myocardial infarctions or ischaemic strokes. Although the underlying biological association between the other biomarkers (elevated triglycerides and low HDL‑ levels) and CVDs is less clear, there are strong epidemiological correlations that justify the treatment of those deviations (Hudson, 2014).
Dyslipidaemias are a major risk factor for cardiovascular disease (the leading cause of death worldwide), and their treatment is dominated by the statin class. However, there is a large population of patients who are intolerant or unresponsive to statins. This analysis examines the new classes of drugs that are in development for dyslipidaemia — in particular the PCSK9 inhibitors and CETP inhibitors — and discusses their likely effects on the dyslipidaemia market in the future…..
Hudson (2014) From the Analyst’s Couch: They dyslipidemia market. Nature Reviews Drug Discovery. Available from: http://www.nature.com/nrd/journal/vaop/ncurrent/full/nrd4475.html [Accessed 27 October 2014].